Key result
Direct oral anticoagulants (apixaban, rivaroxaban, and edoxaban) offer predictable pharmacokinetics without routine monitoring, though chromogenic anti-Xa assays are recommended when measurement is needed.
Answers are grounded in this paper and cite their sources.
When clinical circumstances require measuring DOAC plasma concentrations, the chromogenic anti-Xa assay is the preferred accessible method, though LC-MS remains the reference standard.
Traditionally, anticoagulant therapy has been conducted through the administration of vitamin K antagonists (VKAs) and parenteral alternatives. Direct Oral Anticoagulants (DOACs) such as apixaban, rivaroxaban and edoxaban provide the convenience of the VKA in that they are administered orally yet they lack many of the disadvantages associated with VKA therapy. Unlike VKAs, measuring DOAC levels is usually unnecessary. However, there are instances with plasma concentrations should be determined. The chromogenic anti-Xa assay is the best linear quantitative assay that is easily accessible to most clinical laboratories for this purpose. However, since the calibrators and controls for apixaban, rivaroxaban and edoxaban are awaiting Federal Drug Administration (FDA) clearance, measurement may have to be performed using the Prothrombin Time assay that lacks the sensitivity of the chromogenic anti-Xa. Results should be periodically verified using liquid chromatography in tandem with mass spectrometry which is the reference method for measuring DOAC levels in plasma. A AB BB BR RE EV VI IA AT TI IO ON NS S: : AF-atrial fibrillation, DOACdirect oral anticoagulant, DVT -deep vein thrombosis, FDA -Food and Drug Administration, HPLC -high performance liquid chromatography, LMWH -low molecular weight heparin, PE -pulmonary embolism, PT -prothrombin time, UFH -unfractionated heparin, UPLC -ultra-performance liquid chromatography, VKA -vitamin K antagonist, VTE -venous thromboembolism I IN ND DE EX X T TE ER RM MS S: :
No takes yet. Share an insight, caveat, or question.
Keith Alan DeHaas (2017) conducted a review in Thromboembolic disease and cardiac arrhythmias. Direct Oral Anticoagulants (Apixaban, Rivaroxaban, Edoxaban) vs. Vitamin K antagonists was evaluated. Direct oral anticoagulants (apixaban, rivaroxaban, and edoxaban) offer predictable pharmacokinetics without routine monitoring, though chromogenic anti-Xa assays are recommended when measurement is needed.
Synapse has enriched 10 related papers. Consider them for comparative context: